AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-16 and is reviewed periodically as new material appears.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The defining feature of periodontitis is connective tissue attachment loss which may manifest as deepening of periodontal pockets, gingival recession, or both. This loss of support for the teeth is essentially irreversible damage. Chronic periodontitis is generally slow to moderate in terms of disease progression, although short bursts of increased tissue destruction may occur. Ultimately, tooth loss may occur if the condition is not halted. It is termed localized when less than 30% of sites around teeth are involved, and generalised when more than 30% are involved. clinical attachment loss can be used to determine the severity of the condition, where 1–2 mm is slight, 3–4 mm is moderate and more than 5mm is severe.
Glutamate-5-semialdehyde is a non-proteinogenic amino acid involved in both the biosynthesis and degradation of proline and arginine (via ornithine), as well as in the biosynthesis of antibiotics, such as carbapenems. It is synthesized by the reduction of glutamyl-5-phosphate by glutamate-5-semialdehyde dehydrogenase. In solution in water, the aldehyde is in chemical equilibrium with (S)-1-pyrroline-5-carboxylic acid and this is the form in which many of its biochemical reactions occur.
The car dealership Evans Halshaw is in Sunderland. The car factory owned by Nissan Motor Manufacturing UK between North Hylton and Washington is the largest in the UK. Grundfos, the world's leading pump manufacturer, builds pumps in Sunderland. Calsonic Kansei UK, formerly Magna, make automotive instrument panels and car trim at the Pennywell Industrial Estate. Gestamp UK make automotive components. Smith Electric Vehicles originated in Washington. The LG Electronics microwave oven factory opened in 1989, closed in May 2004, and later became the site of the Tanfield Group. Goodyear Dunlop had their only UK car tyre factory next to the Tanfield site until its 2006 closure. BAE Systems Global Combat Systems moved to a new £75 million factory at the former Goodyear site in 2011, where they make large calibre ammunition for tanks and artillery. The government's child benefit office is in Washington. Liebherr build cranes next to the Wear at Deptford. The outdoor clothing company Berghaus is in Castletown. Vaux Breweries, who owned Swallow Hotels, closed in 1999. ScS Sofas are on Borough Road. There are many call centres in Sunderland, notably EDF Energy at the Doxford International Business Park, which is also the home of the headquarters of the large international transport company Arriva and Nike UK. Rolls-Royce planned to move their production of fan and turbine discs to BAE Systems' new site in 2016.
Sources: en.wikipedia.org
== Clinical Significance == Deficiency of glutaryl-CoA dehydrogenase causes glutaric acidemia type 1, an autosomal recessive metabolic disorder.In this disorder, impaired metabolism of glutaryl-CoA is associated with elevated levels of organic acids, including glutaric acid and 3-hydroxyglutaric acid .
A farmer, George Smith, working under landlord the Duke of Gordon, was the first person in Scotland to take out a licence for a distillery under the new act, founding the Glenlivet Distillery in 1824, to make single malt Scotch. Some of the distilleries which started legal operations in the next few years included Bowmore, Strathisla, Balblair, and Glenmorangie; all remain in business today. Two events helped to increase whisky's popularity. The first was the introduction in 1831 of the column still. Aeneas Coffey patented a refined version of a design originally created by Robert Stein, based on early innovations by Anthony Perrier, for the new type of still which produced whisky much more efficiently than the traditional pot stills. The column still allowed for continuous distillation, without the need for cleaning after each batch was made. This process made manufacturing more affordable by performing the equivalent of multiple distillation steps. The new still dramatically increased production and the resultant whisky was less intense and smoother, making it more popular. Secondly, there was a shortage of wine and brandy in France, significant by 1880, due to phylloxera, a parasitic insect, destroying many vineyards, which led to a surge in demand for whisky. By the 1890s, almost forty new distilleries had opened in Scotland. In a speculative boom, the Edinburgh blenders Pattisons Ltd. came to prominence before spectacularly failing. In the downturn, The Distillers Company were able to buy up other firms' assets.
He successfully pitched the idea to Valve president Gabe Newell and others on the team by telling them: "Let’s take video games outside of the bunkers and the corridors and the hallways, and let’s have a whole world that feels real and very intense. And then when any event happens in this world, the impact will be much stronger." After this, City 17's architecture and atmosphere took inspiration from Soviet-era Sofia, Belgrade, and St. Petersburg—mainly Sofia—as well as Franz Kafka's writings and George Orwell's novel Nineteen Eighty-Four. Antonov collected images of the Gare d'Austerlitz train station in Paris to use as reference for the station the player starts the game from. Antonov made sure City 17 made sense not only in terms of level design, but as an actual living space, with "coherence and consistency" in street layouts and architecture "that shouldn’t be noticed by the players", but nonetheless is subconsciously felt by them. He also had to determine how the game's environments would interact with the advanced lighting technology offered by Valve's new Source game engine. Half-Life 2 writer Marc Laidlaw said that Antonov served as a bridge between "the daily practical ‘Yes, but how do I actually build it?’ needs of [the] level designers, and my vague, atmospheric, ‘It should sorta feel like’ suggestions"—as well as between the literary themes of the story and the design of City 17. Antonov later said that the game's development provided him a far more effective education on design than the ArtCenter College of Design did.
Sources: en.wikipedia.org
== History == The history of light therapy can be traced back to ancient Egypt and India, where therapy with natural sunlight was first used to treat leucoderma. In the 1850s, Florence Nightingale's advocacy of exposure to clean air and sunlight for health restoration also contributed to the initial development of light therapy for treatments. Later, Downes and Blunt's experiment in 1877 suggested sunlight's effect on fungal growth inhibition, which further evidenced the efficiency of light therapy . The modern use of light therapy with artificial lights started in the late 19th century. The Danish Nobel Prize winner in medicine and physiology, Niels Finsen, pioneered the use of light as a therapy for skin tuberculosis (lupus vulgaris). His creation of the light device "Finsen lamp" as a lupus vulgaris treatment marked the beginning of modern light therapy. The application of LED lights in cosmetology became more popular in the 1980s, particularly for acne recovery, due to its ability of collagen production. Since the early 2000s, the use of LED light therapy in the medical field has become more versatile, including treatment for skin conditions, chronic diseases, and the realignment of human circadian rhythm. It has now become a commonly used therapy in both the beauty and medical fields.
== Exposure and health effects == Humans can be exposed to THS through inhalation, skin contact, or ingestion. Many common surfaces can accumulate THS compounds, including furnishings, walls, flooring, and clothes. THS is thought to potentially cause more harm to infants and young children because younger children are more likely to put their hands in their mouths or be cuddled up to a smoker with toxins on their skin and clothes. Infants also crawl on the floor and eat from their hands without washing them first, ingesting the toxins into their still-developing respiratory and immune systems. According to a study conducted by Northrup, 22% of infants and children are exposed to SHS/THS in their homes each year, comprising a major proportion of the 126 million nonsmokers exposed to harmful tobacco products annually. Though research is limited, many harmful health effects have been linked to THS exposure. THS has the potential to impair wound healing by altering the body's natural anti-inflammatory response, remodel respiratory structure due to increased collagen deposits in airways, and cause permanent damage to DNA. Other health effects include asthma, increased cough morbidity, and other respiratory conditions. If pregnant mothers are exposed to THS, it can slow fetal lung development in the third trimester. In children, THS exposure has also been linked to sudden infant death syndrome (SIDS) as a potential cause factor, and has also been linked to cognitive and memory deficits in growing children.
Composition ornament ("compo") is a mouldable thermoplastic compound, consisting of powdered chalk mixed with collagen (hide glue), resin (pine rosin) and linseed oil in ratio 1 to 1 to 1 by volume.; worked either by hand or more usually pressed into moulds to produce decorative work. It's now most commonly seen as part of gilded picture frames, but was in use for many smaller decorative mouldings from the later part of the Baroque period.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.